Compare Orion Office REIT Inc (ONL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs 10X Genomics Inc — how do they compare? Orion Office REIT Inc trades at $2.2 (market cap $125.50M), while 10X Genomics Inc trades at $82.03 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 80.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and 10X Genomics Inc for 92 Days on average.
| ONL | TXG | |
|---|---|---|
Market Cap | $125.50M | $10.07B |
Volume | 303,276 | 5,657,286 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $97.74 |
52-Week Low | $1.93 | $11.48 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $542.43M | $9.59B |
Dividend Yield | 3.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.27, down 2.58% today, with a bearish technical signal from moving averages but bullish oscillators. The company shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Analyst consensus is split 50/50 buy/hold, while recent news highlights strategic portfolio repositioning and Q2 2026 earnings beat.
Outlook remains challenged by negative profitability and high debt levels, though low P/B of 0.2 suggests deep value. Key risks include office sector headwinds and cash flow volatility. Investment appeal hinges on successful execution of turnaround strategy amid weak fundamental trends.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
